|
| Status |
Public on Aug 01, 2013 |
| Title |
HEP-d1 |
| Sample type |
RNA |
| |
|
| Source name |
FACS-isolated HepG2 cells expressing dominant negative TCF4 GFP expression plasmids, rep1
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: HepG2 liver cancer
expression: dominant negative TCF4 GFP expression plasmids
|
| Treatment protocol |
LS174T and HepG2 cells were transciently transfected with a DN-TCF4 GFP-expression vector using Lipofectamine 2000, and cells with high-level GFP expression were isolated 48 hours post transfection using flow cytometry.
|
| Growth protocol |
LS174T and HepG2 cells were cultured in DMEM supplemented with 10% FBS. HepG2 cells were grown on cell cultured dishes coated with collegan I.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated using TRIZOL Reagent (Invitrogen, 15596-026) and purified by RNeasy Mini Kit (QIAGEN, 74104).
|
| Label |
biotin
|
| Label protocol |
300 ng of total RNA were labeled for each sample using the GeneChip WT cDNA Synthesis and Amplification Kit and WT Terminal Labeling Kit (Affymetrix, 900673 and 900671).
|
| |
|
| Hybridization protocol |
13.5 mg of fragmented biotinylated cRNA was fragmented and hybridized for 16 hr at 45C on human genechip 1.0 st arrays. Arrays were washed and stained in the Affymetrix Fluidics Station 450.
|
| Scan protocol |
Arrays were scanned with the GeneChip Scanner 3000 7G
|
| Description |
Gene expression data from human HepG2 liver cancer cell line.
|
| Data processing |
Data were analyzed by dChIP
|
| |
|
| Submission date |
Apr 29, 2013 |
| Last update date |
Aug 01, 2013 |
| Contact name |
Junhao Mao |
| E-mail(s) |
[email protected]
|
| Organization name |
University of Massachusetts Medical School
|
| Department |
Cancer Biology
|
| Street address |
364 Plantation Street, LRB 417
|
| City |
Worcester |
| State/province |
MA |
| ZIP/Postal code |
01605 |
| Country |
USA |
| |
|
| Platform ID |
GPL6244 |
| Series (1) |
| GSE46465 |
Transcriptional responses of human colon and liver cancer cells to TCF inhibition. |
|
